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Abstracts:  
Human Immunodeficiency Virus Type 1 (HIV-1) displays extensive genetic diversity globally that poses a serious challenge in designing suitable 
therapeutic measures for protective immune responses in the host.  After the first detection of AIDS cases in 1986, India now has the third largest 
HIV epidemic in world. The HIV-1 epidemic in India is still growing with introduction of new strains/subtypes and this creates a serious problem 
for the clinician and basic science researchers to find the effective measures. Neighboring countries in the North and North-eastern regions play 
an important role in the HIV-1 pandemic. An extensive multinational collaborative research effort is needed in order to identify the risk groups 
and geographic locales is required to monitor HIV-1 spread in Asia and to produce a successful preventive program. 
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Background 
The first case of HIV infection and AIDS was documented in India in 
1986, within five years of the first description of AIDS in North 
America. The progress of the HIV epidemic was relatively slow, 
initially. Over the years, the number of HIV infected persons increased 
and it is a major public health problem now. The estimated number of 
HIV-1 infected individuals in India was 2.5 million in 2008, which 
placed India at third place behind South Africa and Nigeria [1]. 
 
HIV-1 Genetic Diversity in India 
The expanding nature of the HIV-1 epidemic and introduction of 
Circulating Recombinant Forms (CRFs) and Unique Recombinant 
Forms (URFs) along with subtypes in addition to the predominant 
Subtype C, poses a serious clinical and public health concern in India 
from the very beginning of this pandemic. The genetic analysis of 
HIV-1 from different parts of India reveals Subtype C strains as a 
predominant. However, the introduction of other subtypes in high risk 
group HIV-1 infected patients, primarily female commercial sex 
workers (CSWs) and intravenous drug users (IDUs), created 
challenges for therapy and vaccine development programs. A 
diversified HIV-1 pandemic has been found in different regions of 
India. The South Indian epidemic is mostly conserved in nature; 
although, there is the co-existence of Subtypes C, B and CRF08_BC. 
A group lead by Dr. Udaykumar Ranga at Jawaharlal Nehru Centre for 
Advance Scientific Research, also found novel B/C recombinant 
viruses in these populations that are not represented elsewhere. 
 
The most diverse pattern was observed in the North and North-eastern 
regions of India. Work in the North East by Dr. Sekhar Chakrabarti 
and his colleagues at the National Institute of Cholera and Enteric 
Disease, Kolkata and National AIDS Research Institute (NARI), Pune, 
lead by Dr. Ramesh Paranjape, revealed the presence of Subtype C, 
Thai B, B and novel B/C recombinants of different ancestral origins in 
CSWs and IDUs. The reports from Maharastra, a south-western state 
also found diverse patterns. The highest divergent strains were found 
in Northern region from the initial stage of its characterizations. 
Reports from Dr. Shahid Jameel at International Centre for Genetic 
Engineering and Biology, Dr. Pradeep Seth at All India Institute of 
Medical Science, and their co-workers found different subtypes 
including C, A, B, and E in North India. Recently Dr. Akhil Banerjea 
and his group at the National Institute of Immunology have reported 
intra- and inter-B/C recombinants with similarity to corresponding 
strains in China. According to several Indian researchers, the 
prevalence of other predominant HIV-1 subtypes in neighboring 
countries primarily including Pakistan, China, Thailand and Myanmar, 
plausibly play important determinative factors in   HIV-1 
epidemiology in India [2,3]. Co-circulation of different subtypes in 
high risk populations mainly among CSWs and IDUs opens a wide 
array of chances of generation of intra- and inter-recombinant strains 
in India. Recombinant strains already pose serious global health 
problems in countries such as China and on the African continent.  
 
Vaccine research 
At the risk of losing  the battle to control AIDS with slogans, 
condoms, foreign grants from  World Bank, National Institute of 
Health, USA (check numbers of grants on  http://crisp.cit.nih.gov/), 
and Bill and Melinda Gates Foundation (BMGF) , the Indian 
government in 1998 launched a program to develop a vaccine against 
the disease [4]. In India, the first vaccine trial was initiated at NARI 
Pune, in 2005 and was completed in January 2007. This was a Phase I 
study of the Adeno-Associated Virus (AAV) based HIV-1 subtype C 
vaccine tgAAC09. It is a non-pathogenic virus often found in people 
infected with adenoviruses, genetically modified with three HIV-1 
subtype C Gag, Protease and part of the reverse transcriptase gene. 
The second phase I trial was recently completed at the Tuberculosis 
Research Center (TRC) with TBC-M4; a modified Vaccinia Ankara 
(MVA) based vaccine. The International AIDS Vaccine Initiative 
(IAVI) and biotechnology firm Therion Biologics Corporation 
(Cambridge, Massachusetts, USA) with the assistance of Dr. Sekhar 
Chakrabarty, an Indian Scientist from the NICED, Kolkata, designed 
the candidate and manufactured doses of this vaccine for initial 
clinical trials. This 'modified vaccinia Ankara (MVA) vaccine' is a 
genetic modified vaccinia Ankara, a harmless version of pox virus, 
incorporated with genetic material from six HIV genes (env, pol, gag, 
rev, nef and tat) from an Indian isolate of subtype C [5]. 62 people 
have been enrolled in these trials and the vaccines have been found to 
be safe and well tolerated. Expanding on the results and success of the 
previous trials in India, a new Phase I trial is being considered in both 
NARI and TRC [6]. 
 
Challenges and Possible Solutions 
The genetic hypervariability of HIV-1, persistence of latent integrated 
proviral DNA, differential transmission route, limited utility and 
relevance of animal models, time consuming and costly clinical trials 
among motivated volunteer participants, poses unprecedented 
scientific and organizational challenges to develop vaccine and 
therapeutic success against this disease. As the transmission routes of 
several HIV-1 strains have been traced among several neighboring 
countries, an active scientific coordination is needed between these 
countries in order to identify the risk groups and geographic locales 
where new CRFs or multidrug-resistant HIV-1 strains occur and may 
emerge further [7]. National level vigorous research on HIV-1 genetics 
in effective collaboration with clinical and basic science researchers is 
essential for successful and effective therapeutics for all patients 
suffering from this world’s deadly disease. 
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